109 related articles for article (PubMed ID: 21538429)
1. Comment on a systematic review of randomized trials of peginterferon alpha-2a versus peginterferon alpha-2b in chronic hepatitis C.
Singal AK; Jampana SC; Anand BS
Hepatology; 2011 Jun; 53(6):2151. PubMed ID: 21538429
[No Abstract] [Full Text] [Related]
2. Proceed with caution: peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials.
Kershenobich D; Muñoz L; Malé R; Gaytan J; Sánchez F
Hepatology; 2010 Dec; 52(6):2240-1; author reply 2241-2. PubMed ID: 21105116
[No Abstract] [Full Text] [Related]
3. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
[TBL] [Abstract][Full Text] [Related]
4. [APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():74-5. PubMed ID: 15373058
[No Abstract] [Full Text] [Related]
5. Comparison of peginterferon and interferon in treating Chinese patients with chronic hepatitis C.
Zhao S; Liu E; Yu H; Yang H; Xun M; Xue X; Song J; Xu K; Chu Y
Hepatogastroenterology; 2008; 55(84):1047-54. PubMed ID: 18705326
[TBL] [Abstract][Full Text] [Related]
6. Antiviral effect of peginterferon alfa-2b and alfa-2a compared.
Jansen PL; Reesink HW
J Hepatol; 2006 Aug; 45(2):172-3. PubMed ID: 16797101
[No Abstract] [Full Text] [Related]
7. Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections.
Torriani FJ; Chung RT
ACP J Club; 2005; 142(1):A12; author reply A13. PubMed ID: 15656540
[No Abstract] [Full Text] [Related]
8. Meta-analysis: pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis C.
Romero-Gómez M; Planas R; Ampuero J; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Turnes J
Aliment Pharmacol Ther; 2013 Jun; 37(11):1065-73. PubMed ID: 23581537
[TBL] [Abstract][Full Text] [Related]
9. "Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.
Schulze Zur Wiesch J; Pudelski N; Hoepner L; Supplieth M; Buggisch P; Lohse AW; Lüth S
Hepatology; 2011 Apr; 53(4):1405-6; author reply 1407. PubMed ID: 21480360
[No Abstract] [Full Text] [Related]
10. Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.
Craxì A; Piccinino F; Ciancio A; Iannacone C; Deodato B; Golotta C; Ascione A
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):388-95. PubMed ID: 24569819
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study.
Bruno R; Sacchi P; Scagnolari C; Torriani F; Maiocchi L; Patruno S; Bellomi F; Filice G; Antonelli G
Aliment Pharmacol Ther; 2007 Aug; 26(3):369-76. PubMed ID: 17635371
[TBL] [Abstract][Full Text] [Related]
12. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.
Keam SJ; Cvetković RS
BioDrugs; 2009; 23(1):63-8. PubMed ID: 19344193
[TBL] [Abstract][Full Text] [Related]
14. [Effect of peginterferon alpha-2a combinated with ribavirin in the treatment of rebound patient with chronic hepatitis C: a case report].
He Q; Li ZY
Zhonghua Gan Zang Bing Za Zhi; 2010 Oct; 18(10):794. PubMed ID: 21059303
[No Abstract] [Full Text] [Related]
15. [Treatment of chronic hepatitis C with peginterferon alpha-2a and the factors influencing the effect of this treatment].
Jin GD; Gong QM; Mao HJ; Xu DZ; Lu ZM
Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):302-4. PubMed ID: 15850524
[No Abstract] [Full Text] [Related]
16. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
19. Equal efficacy between the two types of peginterferon on HCV: a matter of relapse?
Brochot E; Nguyen-Khac E; Duverlie G
Antiviral Res; 2013 Apr; 98(1):1-3. PubMed ID: 23422645
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
Taylor LE; Rich JD; Tashima KT
N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15564553
[No Abstract] [Full Text] [Related]
[Next] [New Search]
